{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:48:02Z","timestamp":1794055682644,"version":"4.8.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eclinm.2025.103371","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:59:21Z","timestamp":1754600361000},"page":"103371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10)"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-4602","authenticated-orcid":false,"given":"Malgorzata","family":"Mikulska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Oltolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Reigadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-5470","authenticated-orcid":false,"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/cid\/ciad628","article-title":"High rates of acquisition of toxigenic clostridioides difficile colonization without subsequent infection during acute lymphoblastic leukemia treatment in children","volume":"78","author":"Yang","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib2","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.bbmt.2014.06.025","article-title":"Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1\/027","volume":"20","author":"Kamboj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib3","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00277-020-04274-1","article-title":"Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy","volume":"99","author":"Ballo","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa038","article-title":"Exploratory evaluation of Bezlotoxumab on outcomes associated with clostridioides difficile infection in MODIFY I\/II participants with cancer","volume":"7","author":"Cornely","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciy171","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence","volume":"67","author":"Gerding","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib6","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/jac\/dkx005","article-title":"Risk factors and impact of clostridium difficile recurrence on haematology patients","volume":"72","author":"Scappaticci","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.bbmt.2013.07.022","article-title":"Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors","volume":"19","author":"Alonso","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib8","doi-asserted-by":"crossref","first-page":"998.e9","DOI":"10.1016\/j.cmi.2015.07.016","article-title":"Low sensitivity of fecal toxin A\/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients","volume":"21","author":"Erb","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.diagmicrobio.2019.04.002","article-title":"Laboratory comparison between cell cytotoxicity neutralization assay and ultrasensitive single molecule counting technology for detection of Clostridioides difficile toxins A and B, PCR, enzyme immunoassays, and multistep algorithms","volume":"95","author":"Sandlund","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3343\/alm.2021.41.2.171","article-title":"Laboratory diagnostic methods for clostridioides difficile infection: the first systematic review and meta-analysis in korea","volume":"41","author":"Chung","year":"2021","journal-title":"Ann Lab Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1473-3099(13)70200-7","article-title":"Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection","volume":"13","author":"Planche","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the molecular test era","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib13","doi-asserted-by":"crossref","first-page":"471.e1","DOI":"10.1016\/j.jtct.2023.04.010","article-title":"An algorithm addressing the problem of overdiagnosis of clostridioides difficile infections in hematopoietic stem cell transplantation recipients: effects on C. difficile infection rates and patient outcomes","volume":"29","author":"Ford","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13279","article-title":"Are Clostridioides difficile infections being overdiagnosed in hematopoietic stem cell transplant recipients?","volume":"22","author":"Ford","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ajic.2023.11.022","article-title":"Analysis of health care facility-onset Clostridioides difficile infection (CDI) in a hematopoietic cell transplant (HCT) unit: a call for diagnostic stewardship in a complex patient population","volume":"52","author":"Swetky","year":"2024","journal-title":"Am J Infect Control"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103371_bib16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1900623","article-title":"Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation","volume":"382","author":"Peled","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejcsup.2007.06.001","article-title":"The first European conference on infections in leukaemia: why and how?","volume":"5","author":"Cordonnier","year":"2007","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103371_bib18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103371_bib19","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1473-3099(21)00203-6","article-title":"Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bbmt.2014.02.022","article-title":"Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis","volume":"20","author":"Vehreschild","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157839","article-title":"Clostridium difficile infections amongst patients with haematological malignancies: a data linkage study","volume":"11","author":"Selvey","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ajic.2018.09.027","article-title":"Clostridioides difficile colonization and infection in patients with newly diagnosed acute leukemia: incidence, risk factors, and patient outcomes","volume":"47","author":"Ford","year":"2019","journal-title":"Am J Infect Control"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhin.2019.12.017","article-title":"Excess burden associated with Clostridioides difficile infection in haematological patients occurring during hospitalization with induction chemotherapy in the USA","volume":"104","author":"Duhalde","year":"2020","journal-title":"J Hosp Infect"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib24","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.bbmt.2014.06.001","article-title":"Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies","volume":"20","author":"Zacharioudakis","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.eclinm.2025.103371_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.801475","article-title":"Prevalence of Clostridium difficile infection in the hematopoietic transplantation setting: update of systematic review and meta-analysis","volume":"12","author":"Luo","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib26","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41598-024-56336-3","article-title":"Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the polish adult leukemia group","volume":"14","author":"Piekarska","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41409-022-01896-z","article-title":"The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study","volume":"58","author":"Ramanathan","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.14122","article-title":"Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy","volume":"112","author":"Garcia-Pouton","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.eclinm.2025.103371_bib29","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12185-014-1577-z","article-title":"Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients","volume":"99","author":"Guddati","year":"2014","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib31","doi-asserted-by":"crossref","first-page":"94.e1","DOI":"10.1016\/j.bbmt.2020.10.005","article-title":"Impact of a clostridioides difficile testing computerized clinical decision support tool on an adult stem cell transplantation and hematologic malignancies unit","volume":"27","author":"Nix","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib32","doi-asserted-by":"crossref","first-page":"176.e1","DOI":"10.1016\/j.jtct.2020.10.009","article-title":"Clostridioides difficile infection and risk of acute graft-versus-host disease among allogeneic hematopoietic stem cell transplantation recipients","volume":"27","author":"Jabr","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1590\/S0036-46652014000400010","article-title":"Incidence of diarrhea by Clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death","volume":"56","author":"Spadao","year":"2014","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1017\/ice.2018.83","article-title":"Clinical characteristics and outcomes of hematologic malignancy patients with positive Clostridium difficile toxin immunoassay versus polymerase chain reaction test results","volume":"39","author":"Ziegler","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/1078155221998735","article-title":"Evaluating Clostridioides difficile infection (CDI) treatment duration in hematology\/oncology patients receiving concurrent non-CDI antibiotics","volume":"28","author":"Keats","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-009-0772-0","article-title":"Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia","volume":"89","author":"Schalk","year":"2010","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib134","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz436","article-title":"Microbiological characterization and clinical outcomes after extended-pulsed fidaxomicin treatment for clostridioides difficile Infection in the EXTEND study","volume":"6","author":"Wilcox","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib38","doi-asserted-by":"crossref","first-page":"814.e1","DOI":"10.1016\/j.jtct.2024.05.013","article-title":"Multiplexed gastrointestinal PCR panels for the evaluation of diarrhea in hematopoietic stem cell transplantation recipients","volume":"30","author":"Ford","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.eclinm.2025.103371_bib39","first-page":"1","article-title":"Multiplexed gastrointestinal PCR panels for the evaluation of diarrhea in patients with acute leukemia","author":"Ford","year":"2024","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103371_bib42","article-title":"How I approach diarrhea in hematological transplant patients: a practical tool","volume":"25","author":"Castillo Almeida","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"10S","key":"10.1016\/j.eclinm.2025.103371_bib43","article-title":"S2743 CAR T-cell therapy-induced pseudomembranous colitis mimicking C. difficile infection","volume":"119","author":"Bashir Hamidu","year":"2024","journal-title":"ACG"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib45","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1188\/16.CJON.E100-E105","article-title":"Diarrhea in multiple myeloma: a review of the literature","volume":"20","author":"Faiman","year":"2016","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QCO.0000000000000753","article-title":"Recent advances in Clostridioides difficile infection epidemiology, diagnosis and treatment in children","volume":"34","author":"Kociolek","year":"2021","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cmi.2022.03.001","article-title":"How to: clostridioides difficile infection in children","volume":"28","author":"Krutova","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib48","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-062307","article-title":"Clostridioides difficile infection in children: recent updates on epidemiology, diagnosis, therapy","volume":"152","author":"Shirley","year":"2023","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103371_bib49","article-title":"Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient","volume":"25","author":"Lo Porto","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/INF.0000000000003126","article-title":"Epidemiologic and clinical characteristics of clostridioides difficile infections in hospitalized and outpatient pediatric oncology and hematopoietic stem cell transplant patients","volume":"40","author":"Barbar","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/imj.13027","article-title":"Australasian society of infectious diseases updated guidelines for the management of clostridium difficile infection in adults and children in Australia and New Zealand","volume":"46","author":"Trubiano","year":"2016","journal-title":"Intern Med J"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2021.2328","article-title":"Prevalence of detection of clostridioides difficile among asymptomatic children: a systematic review and meta-analysis","volume":"175","author":"Tougas","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib53","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/MPG.0000000000001264","article-title":"Clostridium difficile infection in children: a review","volume":"63","author":"Borali","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2025.103371_bib55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/669081","article-title":"Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy","volume":"34","author":"Wang","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365520802321238","article-title":"Absence of pseudomembranes in clostridium difficile-associated diarrhea in patients using immunosuppression agents","volume":"44","author":"Nomura","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.eclinm.2025.103371_bib58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.anaerobe.2016.04.001","article-title":"Neutrophil-mediated inflammation in the pathogenesis of clostridium difficile infections","volume":"41","author":"Jose","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.eclinm.2025.103371_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.anaerobe.2017.02.014","article-title":"Role of the leukocyte response in normal and immunocompromised host after clostridium difficile infection","volume":"45","author":"Vargas","year":"2017","journal-title":"Anaerobe"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib60","doi-asserted-by":"crossref","first-page":"e00037","DOI":"10.1128\/CVI.00037-17","article-title":"Cytokines are markers of the clostridium difficile-induced inflammatory response and predict disease severity","volume":"24","author":"Yu","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib61","first-page":"187","article-title":"Performance of clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer","volume":"31","author":"De-la-Rosa-Martinez","year":"2023","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib62","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/tid.12267","article-title":"Risk factors for recurrent clostridium difficile infection in hematopoietic stem cell transplant recipients","volume":"16","author":"Huang","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib63","first-page":"2039","article-title":"Predictors of mortality attributable to clostridium difficile infection in patients with underlying malignancy","volume":"22","author":"Yoon","year":"2014","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib64","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1099\/jmm.0.000774","article-title":"Detection of toxigenic clostridium difficile colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation","volume":"67","author":"Vaughn","year":"2018","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jmii.2020.02.002","article-title":"Recommendations and guidelines for the treatment of clostridioides difficile infection in Taiwan","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF02054220","article-title":"Severe clostridium difficile colitis","volume":"38","author":"Rubin","year":"1995","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.eclinm.2025.103371_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.anaerobe.2015.08.002","article-title":"Factors predictive of severe clostridium difficile infection depend on the definition used","volume":"37","author":"Khanafer","year":"2016","journal-title":"Anaerobe"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib68","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/cir1035","article-title":"Epidemiology and outcomes of clostridium difficile infections in hematopoietic stem cell transplant recipients","volume":"54","author":"Alonso","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/phar.1914","article-title":"Evaluation of risk factors for clostridium difficile infection in hematopoietic stem cell transplant recipients","volume":"37","author":"Scardina","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib70","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.bbmt.2012.02.010","article-title":"Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome","volume":"18","author":"Willems","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13770","article-title":"Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: a prospective multinational study","volume":"24","author":"Blumberg","year":"2022","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090158","article-title":"Early clostridium difficile infection during allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Kinnebrew","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12648","article-title":"Risk factors for the development of clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: a single-center study in Quebec, Canada","volume":"19","author":"Lavallee","year":"2017","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib74","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.medmal.2017.07.002","article-title":"Treating clostridium difficile infection in patients presenting with hematological malignancies: are current guidelines applicable?","volume":"47","author":"Robin","year":"2017","journal-title":"Med Mal Infect"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1086\/511792","article-title":"Severity of clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system","volume":"28","author":"Dubberke","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/ice.2015.270","article-title":"Assessment of clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin","volume":"37","author":"Housman","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103371_bib77","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jiac.2018.05.010","article-title":"Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan","volume":"24","author":"Mikamo","year":"2018","journal-title":"J Infect Chemother"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib78","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad622","article-title":"Comparative effectiveness of fidaxomicin vs vancomycin in populations with immunocompromising conditions for the treatment of clostridioides difficile infection: a single-center study","volume":"11","author":"Alsoubani","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hemonc.2018.05.001","article-title":"Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of clostridium difficile infections in allogeneic stem cell transplant","volume":"11","author":"Prohaska","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103371_bib81","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.01120-13","article-title":"Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with clostridium difficile-associated diarrhea","volume":"57","author":"Clutter","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"10.1016\/j.eclinm.2025.103371_bib82","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","article-title":"Resolution of clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin","volume":"31","author":"Cornely","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib84","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10096-019-03525-y","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses","volume":"38","author":"Cornely","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2025.103371_bib85","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55 Suppl 2","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2025.103371_bib86","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/cis440","article-title":"Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"55 Suppl 2","author":"Nerandzic","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib87","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmi.2023.09.002","article-title":"The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis","volume":"30","author":"Stabholz","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103371_bib89","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1473-3099(18)30285-8","article-title":"Comparative efficacy of treatments for clostridium difficile infection: a systematic review and network meta-analysis","volume":"18","author":"Beinortas","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib91","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of clostridium difficile-associated diarrhea","volume":"22","author":"Wenisch","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"8358","key":"10.1016\/j.eclinm.2025.103371_bib92","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for clostridium-difficile-associated diarrhoea and colitis","volume":"2","author":"Teasley","year":"1983","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1078155217740945","article-title":"Clostridium difficile treatment in neutropenic patients: clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy","volume":"25","author":"Tieu","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib94","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1078155213490004","article-title":"A retrospective review of metronidazole and vancomycin in the management of clostridium difficile infection in patients with hematologic malignancies","volume":"20","author":"Parmar","year":"2014","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib95","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/antibiotics8040173","article-title":"Effective dosage of oral vancomycin in treatment for initial episode of clostridioides difficile infection: a systematic review and meta-analysis","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103371_bib96","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40268-014-0067-3","article-title":"Stability and recovery of DIFICID(\u00ae) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube","volume":"14","author":"Tousseeva","year":"2014","journal-title":"Drugs R D"},{"key":"10.1016\/j.eclinm.2025.103371_bib97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2016.12.020","article-title":"Successful treatment of severe clostridium difficile infection by administration of crushed fidaxomicin via a nasogastric tube in a critically ill patient","volume":"55","author":"Arends","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib98","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s13054-019-2648-6","article-title":"Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)","volume":"23","author":"Manthey","year":"2019","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","article-title":"Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis","volume":"9","author":"Sholeh","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cmi.2017.10.008","article-title":"The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent clostridium difficile ribotypes, 2011-2014","volume":"24","author":"Freeman","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jhin.2012.12.019","article-title":"Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe clostridium difficile infection","volume":"85","author":"Bass","year":"2013","journal-title":"J Hosp Infect"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib102","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2015.06.017","article-title":"Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation","volume":"21","author":"Satlin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103371_bib103","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/cid\/ciz1115","article-title":"Does addition of intravenous metronidazole to oral vancomycin improve outcomes in clostridioides difficile infection?","volume":"71","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103371_bib104","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/phar.2393","article-title":"Evaluation of addition of intravenous metronidazole to oral vancomycin therapy in critically ill patients with non-fulminant severe clostridioides difficile infection","volume":"40","author":"Vega","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/civ409","article-title":"The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with clostridium difficile infection","volume":"61","author":"Rokas","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103371_bib106","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmi.2016.08.017","article-title":"Use of intravenous tigecycline in patients with severe clostridium difficile infection: a retrospective observational cohort study","volume":"22","author":"Gergely Szabo","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib107","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10096-019-03756-z","article-title":"Tigecycline for the treatment of patients with clostridium difficile infection: an update of the clinical evidence","volume":"39","author":"Kechagias","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib108","doi-asserted-by":"crossref","first-page":"e00001","DOI":"10.1128\/aac.00001-22","article-title":"Impact of tigecycline on C. difficile outcomes: case series and propensity-matched retrospective study","volume":"66","author":"Phillips","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib109","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10096-018-3344-1","article-title":"Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)","volume":"37","author":"Vehreschild","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103371_bib110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12879-016-1657-1","article-title":"The efficacy of intracolonic vancomycin for severe clostridium difficile colitis: a case series","volume":"16","author":"Akamine","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib111","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.ccm.0000907652.88583.9c","article-title":"481: intravenous immunoglobulin (IVIG) for severe or fulminant clostridium difficile infection","volume":"51","author":"Nuti","year":"2023","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib112","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijid.2008.11.012","article-title":"The role of immunoglobulin for the treatment of clostridium difficile infection: a systematic review","volume":"13","author":"O'Horo","year":"2009","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-019-03447-3","article-title":"Diverting loop ileostomy with colonic lavage as an alternative to colectomy for fulminant Clostridioides difficile: a systematic review and meta-analysis","volume":"35","author":"McKechnie","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00423-024-03458-x","article-title":"Total abdominal colectomy versus diverting loop ileostomy with colonic lavage for fulminant clostridium difficile colitis: an updated systematic review and meta-analysis of outcomes","volume":"409","author":"Aljaafreh","year":"2024","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103371_bib115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/jcag\/gwab023","article-title":"Fecal microbiota transplantation for severe or fulminant clostridioides difficile infection: systematic review and meta-analysis","volume":"5","author":"Song","year":"2022","journal-title":"J Can Assoc Gastroenterol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib116","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciw731","article-title":"Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial","volume":"64","author":"Hota","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103371_bib117","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/cid\/cix529","article-title":"Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent clostridium difficile infection","volume":"65","author":"Sirbu","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib118","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103371_bib119","first-page":"867","article-title":"Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis","volume":"80","author":"Tedesco","year":"1985","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib120","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jmii.2021.02.002","article-title":"Clostridioides difficile infection in patients with hematological malignancy: a multicenter study in Taiwan","volume":"54","author":"Hung","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"issue":"e1","key":"10.1016\/j.eclinm.2025.103371_bib121","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1136\/ejhpharm-2020-002574","article-title":"Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study","volume":"29","author":"Milenkovic","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib122","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2019.06.021","article-title":"Oral vancomycin prophylaxis as secondary prevention against clostridioides difficile infection in the hematopoietic stem cell transplantation and hematologic malignancy population","volume":"25","author":"Morrisette","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib123","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/cid\/ciad606","article-title":"An open-label, randomized trial comparing fidaxomicin with oral vancomycin for the treatment of clostridioides difficile infection in hospitalized patients receiving concomitant antibiotics for concurrent infections","volume":"78","author":"Rao","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib124","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103371_bib125","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41409-023-02115-z","article-title":"Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT","volume":"58","author":"Battipaglia","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103371_bib126","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103371_bib127","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103371_bib128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/cid\/ciy484","article-title":"A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation","volume":"68","author":"Mullane","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103371_bib129","article-title":"Probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children","volume":"12","author":"Goldenberg","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103371_bib130","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103371_bib131","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cmi.2018.02.020","article-title":"Guidance document for prevention of Clostridium difficile infection in acute healthcare settings","volume":"24","author":"Tschudin-Sutter","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eclinm.2025.103371_bib132","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijid.2020.10.039","article-title":"Prevention of clostridioides difficile in hospitals: a position paper of the international society for infectious diseases","volume":"102","author":"Doll","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103371_bib133","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:36:13Z","timestamp":1758616573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":134,"alternative-id":["S2589537025003037"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103371","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10)","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103371"}}